JNCI Cancer Spectrum最新文献

{"title":"Leveraging geospatial data to support an implementation science approach to address lung cancer burden.","authors":"Tesla D Dubois, Alison C Brecher, Donna Edmondson, Evelyn Gonzalez, Charnita Zeigler-Johnson, Linda Fleisher, Shannon M Lynch","doi":"10.1093/jncics/pkaf047","DOIUrl":"https://doi.org/10.1093/jncics/pkaf047","url":null,"abstract":"<p><p>The lung cancer mortality rate in Philadelphia is 16% higher than the national rate, making screening and prevention efforts paramount. To support prevention efforts, Fox Chase Cancer Center operates a comprehensive Tobacco Treatment Program (TTP) that employs an Implementation Science (IS) approach and provides over 1000 individuals with various therapeutic strategies to support smoking cessation. Using TTP as a case study, this brief report describes the adaptation of the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework into a geospatial format. Each dimension of the geospatial RE-AIM framework results in a map that can help identify 1) target areas for intervention (Reach), 2) the degree to which the program is serving those areas (Effectiveness), 3) opportunities for partnership to support delivery (Adoption), 4) contextual factors influencing how the intervention is best delivered (Implementation), and 5) strategies for long-term integration of the intervention (Maintenance). This framework supports targeted, sustainable initiatives.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer treatment outcomes and survival in Botswana by HIV status: Ipabalele study results.","authors":"Surbhi Grover, Rohini Bhatia, Siqi Zhang, Salman Khan, Memory Bvochora-Nsingo, Sebathu Chiyapo, Dawn Balang, Lilie L Lin, Shalini Vinod, Mark N Polizzotto, Natalie Taylor, Karen Canfell, Nicola Zetola, Erle Robertson, Doreen Ramogola-Masire","doi":"10.1093/jncics/pkaf045","DOIUrl":"https://doi.org/10.1093/jncics/pkaf045","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a leading morbidity/mortality cause, frequently co-occurring with human immunodeficiency virus (HIV) positivity, in Botswana. We examined long-term outcomes for Ipabalele study participants receiving curative chemoradiation for locally advanced cervical cancer (2015-2019) by HIV status.</p><p><strong>Methods: </strong>Clinical and outcome data were collected at baseline, treatment completion, and 3 months thereafter. Patients were followed for up to 5 years. Overall survival (OS) was evaluated using Kaplan-Meier curves and Cox regression.</p><p><strong>Results: </strong>The cohort comprised 295 patients [73.8% with HIV, younger at diagnosis (p < .001)] followed for a median of 44.2 months. Complete response was seen in 217/278 (76.1%) patients. Two- and 5-year OS rates were 73.4% and 59.9%, respectively, with no difference by HIV status. OS was associated negatively with advanced disease stage [III: hazard ratio (HR) 13.23, p < .001; IV: HR 7.8, p = .008] and positively with increased radiation (HR 0.977, p = .0005) and chemotherapy (HR 0.85, p = .005). Clinical response was associated negatively with advanced disease (IV: HR 0.113, p = .002) and positively with increased radiation (p = .009). Toxicity did not differ by HIV status. The most common grade-≥-2 non-hematological and hematological toxicities were radiation dermatitis (39.8%) and reduced white blood cell count (66.05%), respectively.</p><p><strong>Conclusions: </strong>In this cervical cancer cohort with good HIV status control, treatment outcomes and OS were associated with disease and treatment factors, not the HIV status. Early screening and education regarding treatment protocols are crucial to improve cervical cancer outcomes in Botswana.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of self-reported exam indications for breast cancer screening.","authors":"Erin J Aiello Bowles, Hongyuan Gao, Lynn E Fleckenstein, Perla Bravo, Michael G Nash, Bryan Comstock, Chris Neslund-Dudas, Jin Mou, Larry G Kessler","doi":"10.1093/jncics/pkaf046","DOIUrl":"https://doi.org/10.1093/jncics/pkaf046","url":null,"abstract":"<p><p>We validated updated National Health Interview Survey questions on mammography indications compared to electronic health records (EHR). We asked 244 Kaiser Permanente Washington members ages 40-74 years and eligible for breast cancer screening to self-report their most recent mammogram reason using a series of new hierarchical yes/no questions. We first asked if they had the mammogram because of a health problem, then as a follow-up test, and last for screening. We compared self-reported reasons to two EHR datasets: procedure/diagnostic codes, and radiologist-defined indications. Self-reported exams for a health problem had 89.2% agreement with codes and 92.2% agreement with radiologist-defined indications. Self-reported exams for follow-up had 87.5% agreement with codes, and 89.3% agreement with radiologist-defined indications. Self-reported exams for screening had 91.4% agreement with codes, and 95.7% agreement with radiologist-defined indications. Self-reported mammogram indications have good agreement with procedure/diagnostic codes and radiologist-reported indications, when asked using this novel hierarchical approach.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mediating role of physical activity on cognitive disparities in cancer survivors.","authors":"Jaimi L Allen, Laura Q Rogers, Michelle Y Martin, Benjamin C Amick","doi":"10.1093/jncics/pkaf023","DOIUrl":"10.1093/jncics/pkaf023","url":null,"abstract":"<p><p>This study examined the association of physical activity (PA) with cognitive difficulties (CD) and education, income, poverty, and age among cancer survivors (CS) using data from the 2020 National Health Interview Survey. Causal mediation analysis was tested using the bootstrapping method to examine associations between PA, cognitive difficulties, and other sociodemographic characteristics. Results showed statistically significant disparities in both CD and physical inactivity among CS with low education, low income, high poverty, and certain age categories. Health disparities related to CD based on race/ethnicity, sex, and age were also identified. Physical activity mediated the relationship between CD and education, income, poverty, and age. Future research is needed to gain deeper insight into the mechanisms of PA-induced health benefits and to develop specific PA prescription guidelines in the subgroups at risk for CD.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between early tumor shrinkage/depth of response and survivals from the ARCAD database.","authors":"Hideaki Bando, Yuriko Takeda, Toshihiro Misumi, Tomomi Nishikawa, Masashi Wakabayashi, Kentaro Yamazaki, Eiji Oki, Jean-Yves Douillard, Cornelis J A Punt, Miriam Koopman, Eric Van Cutsem, Carsten Bokemeyer, Alan P Venook, Heinz-Josef Lenz, Yoshihiko Maehara, Thierry Andre, Qian Shi, Aimery de Gramont, Takayuki Yoshino","doi":"10.1093/jncics/pkaf042","DOIUrl":"https://doi.org/10.1093/jncics/pkaf042","url":null,"abstract":"<p><strong>Background: </strong>Early tumor shrinkage (ETS) and depth of response (DpR) have emerged as potential prognostic indicators in metastatic colorectal cancer (mCRC). However, their associations with overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) in patients receiving anti- epidermal growth factor receptor (anti-EGFR) antibodies or bevacizumab remain unclear.</p><p><strong>Methods: </strong>We analyzed 3,219 treatment-naïve patients with RAS wild-type mCRC from eight randomized studies (CRYSTAL, OPUS, PRIME, CAIRO2, CALGB80405, WJOG4407G, ATOM, PARADIGM) in the Analysis and Research in Cancers of the Digestive System (ARCAD) database. ETS was defined as a ≥ 20% reduction in tumor size at 8 ± 2 weeks, whereas DpR was assessed by maximum tumor shrinkage at nadir. Cox regression models evaluated the associations of ETS and DpR with OS, PFS, and PPS, adjusting for confounders. A two-sided test was conducted with a significance level of 0.05.</p><p><strong>Results: </strong>ETS and DpR significantly stratified OS, PFS, and PPS outcomes across all treatment groups. ETS positivity was associated with improved OS, PFS, and PPS in anti-EGFR and bevacizumab-based therapies, with a trend toward better outcomes in the anti-EGFR group. The DpR analysis revealed optimal cutoff values of 0.55 for anti-EGFR-based therapy and 0.47 for bevacizumab-based therapy to achieve a median OS of approximately 32 months.</p><p><strong>Conclusions: </strong>ETS and DpR serve as valuable prognostic markers in RAS wild-type mCRC, particularly for patients treated with anti-EGFR antibodies. These findings highlight the potential role of ETS and DpR in guiding treatment strategies and improving patient outcomes.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023).","authors":"Rachel D Altshuler, Lori M Minasian, Catherine A Schweppe, Nina S Kadan-Lottick","doi":"10.1093/jncics/pkaf039","DOIUrl":"https://doi.org/10.1093/jncics/pkaf039","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating acute and long-term toxicity in cancer patients. We sought to describe the landscape of CIPN research funded by the National Institutes of Health (NIH) and identify gaps and opportunities.</p><p><strong>Methods: </strong>Using the NIH Query View Report system, we identified 180 competitive grants between 2014-2023 containing text pertaining to CIPN in the Abstract or Specific Aims. These were categorized as preclinical, clinical, or both and described by preclinical model, clinical population, CIPN assessments, and/or clinical trial design. We identified 5 additional NCI-funded trials through the NCORP network pertaining to CIPN.</p><p><strong>Results: </strong>Of 185 studies, 125 were preclinical, 56 clinical, and 4 both preclinical/clinical. Among pre-clinical studies, most studies utilized rodent CIPN models, of which 17% were tumor-bearing. Most preclinical studies investigated paclitaxel; none studied newer immune therapies. The 60 clinical studies were 53% observational and 47% interventional, focusing most frequently on breast cancer, unspecified cancers, and colorectal cancer diagnoses. Overall, 8% included patients <18 years, while a higher proportion included those 18-39 (85%), 40-64 (90%), and ≥65 (92%). Among 28 interventional trials, studies investigated behavioral interventions (39%), pharmacological agents (32%), and devices (29%).</p><p><strong>Conclusions: </strong>The number of CIPN grants awarded by NIH since 2014 represent a substantial investment, but critical gaps and opportunities remain. Preclinically, novel strategies to mimic human CIPN may improve translatability. Important gaps in CIPN-associated cancer diagnoses and therapy exposures, including novel agents, would benefit from future research. Also, clinical studies are needed in young patients with potential long-term CIPN.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curative or non-curative: immunotherapy for advanced melanoma.","authors":"Richard Kelly, Abigail Miller, Rachel Roberts-Thomson, Andrew Haydon","doi":"10.1093/jncics/pkaf041","DOIUrl":"https://doi.org/10.1093/jncics/pkaf041","url":null,"abstract":"<p><p>Advanced melanoma was historically considered incurable, however a 52% 10-year melanoma-specific survival rate from seminal immunotherapy trials challenges that conclusion 1. There is no literature exploring clinicians' discussion of treatment-intent with patients, or whether this represents cure. We performed a multi-center retrospective cohort analysis to examine treatment-intent, using electronic medical records to identify 278 patients with unresectable or stage IV melanoma consented for immunotherapy from 2019-2023. 32 (12%) were consented for curative-intent treatment (CIT). CIT frequency was not significantly influenced by patient or disease characteristics. Patients consented for CIT received significantly higher rates of combination immunotherapy than patients consented for non-curative-intent treatment (NCIT), 76% (16/21) vs 47% (116/246), p 0.022. Among 267 unresectable patients, CIT rates differed significantly between Victoria and South Australia, 14% (20/142) vs 0.8% (1/125), p < .001. Our data confirms variability of documented treatment-intent in advanced melanoma. Further research is needed to understand how this impacts patients.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Medicare payments within the first year of cervical cancer diagnosis, 2010-2019.","authors":"Mohammad A Karim, Ning Zhang, Hui Zhao, Ya-Chen Tina Shih, Lakshmi S M Kodali, Sharon H Giordano, Sanjay Shete","doi":"10.1093/jncics/pkaf043","DOIUrl":"https://doi.org/10.1093/jncics/pkaf043","url":null,"abstract":"<p><p>Assessing Medicare payment trends for cervical cancer care is important to mitigate the financial impact on Medicare. This multiyear cross-sectional study included 65 years and older cervical cancer patients in SEER registries diagnosed between 2010-2019 who had continuous Part A and B Medicare coverage at least 6 months prior to diagnosis and at least within the first year of diagnosis and were not enrolled in any Health Maintenance Organization in this duration. The main outcomes were trends in total and service-specific mean monthly Medicare payments within the first year of a cervical cancer diagnosis. This study included 2147 cervical cancer patients. The mean Medicare payments increased from $8,300 in 2010 to $8,520 in 2019, largely driven by a statistically significant increase in outpatient services costs, from $1,361 to $2,056 (AAPC=5.45, 95%CI 1.38-9.67, P-value=0.008). These findings highlight the need for policy actions to mitigate cervical-cancer-related financial impact on Medicare.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia.","authors":"Julie A Wolfson, Allison C Grimes, Michelle M Nuño, Subhash Ramakrishnan, David S Dickens, Michael E Roth, Wendy Woods, Kandice S Adams, Tawa Alabi, Melissa Beauchemin, Jennifer M Levine, Michele Scialla, Koh B Boayue, Charlotte L Kerber, Olivia Ponce, Sarah Vargas, George J Chang, Wendy Stock, Dawn Hershman, Emily Curran, Anjali Advani, Kristen O'Dwyer, Selina Luger, Jane Jijun Liu, David R Freyer, Lillian Sung, Susan K Parsons","doi":"10.1093/jncics/pkaf033","DOIUrl":"https://doi.org/10.1093/jncics/pkaf033","url":null,"abstract":"<p><strong>Background: </strong>Individuals diagnosed with acute lymphoblastic leukemia (ALL) between 15-39yo (AYA: adolescents and young adults) face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care (GCC) among AYAs with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices.</p><p><strong>Methods: </strong>We assembled a retrospective cohort of 15-39yo AYAs with ALL treated at participating NCORPs between 2012-2016. NCORPs abstracted patient data and completed facility-level questionnaires for each clinical facility (CF: study-defined criteria). The central review committee adjudicated whether treatment was concordant with AYA-specific National Comprehensive Cancer Network ALL guidelines (ie, pediatric-inspired therapy or clinical trial). GCC was described by age, facility model (adult/internal medicine [adult/IM], pediatric, mixed [pediatric services within a general hospital]), and average annual AYA ALL volume. Generalized linear mixed effects models estimated the odds of GCC.</p><p><strong>Results: </strong>AYAs receiving GCC were younger (n = 196, median = 19.5y) than those who did not (n = 31, median = 32.1y). GCC was observed in many 22-39yo (68.8%), and nearly universal in 15-21 y. In multivariable analyses, AYAs at adult/IM CFs had lower odds of GCC (OR = 0.02, 95% CI, 0.0-0.18); there was no statistically significant association between annual AYA ALL volume and receiving GCC. GCC was observed more often in adult/IM and/or mixed CFs with communication between adult/pediatric counterparts, AYA ALL Clinical Pathways, and/or AYA-specific meetings.</p><p><strong>Conclusion: </strong>GCC among AYAs with ALL (specifically pediatric-inspired therapy) at NCORPs is associated with facility model (adult/IM), but not AYA ALL volume. Strategies to improve GCC could include facilitating communication and clinical pathways at adult/IM CFs treating AYA ALL.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergies, partnership outcomes, and lessons learned: A qualitative evaluation of cancer center-coalition engagement.","authors":"Aubrey Villalobos, Paula Darby Lipman, Jennifer Beebe-Dimmer, Evelinn A Borrayo, Katherine J Briant, Amanda Bruegl, Craig Dee, Sarah Chavez, Bettina Drake, Selisha Snowy Johnson, Kara Kikuchi, Jennifer Leeman, Jan Lowery, Jason A Mendoza, Myra Parker, Lisa Purvis, Kelly Wells Sittig, Hayley S Thompson, Mary Wangen, Stephanie B Wheeler","doi":"10.1093/jncics/pkaf038","DOIUrl":"https://doi.org/10.1093/jncics/pkaf038","url":null,"abstract":"<p><strong>Background: </strong>Nine National Cancer Institute (NCI)-Designated Cancer Centers received supplemental funding to expand community outreach and engagement (COE) activities through a partnership with Centers for Disease Control and Prevention (CDC)-funded comprehensive cancer control coalitions. This article reports on an evaluation of these awards focused on organizational relationship synergies and partnership outcomes.</p><p><strong>Methods: </strong>NCI, COE, and coalition representatives co-designed the evaluation, which involved document review and 18 semi-structured interviews with 16 COE and 19 coalition representatives. AI-generated interview transcripts were dual-coded in NVivo 20/R1.</p><p><strong>Results: </strong>The funding generated a diverse collection of projects and partnerships. COE-coalition synergies and lessons learned were evident in the following domains: infrastructure, community and partner engagement, data monitoring, and intervention implementation, evaluation, and dissemination. Outcomes of this funding initiative were evident in the following domains: strengthened partnerships, expanded knowledge, improved health or healthcare programs and policies, and thriving communities.</p><p><strong>Conclusions: </strong>Fostering COE-coalition partnerships created opportunities to leverage synergies and build capacity for engagement across multiple domains, contributing to enhanced trust and implementation of interventions across the cancer continuum. The findings provide examples and lessons about synergistic opportunities for cancer centers and coalitions to capitalize on. Successful collaborative relationships were based on identifying shared goals and complimentary expertise and roles, sharing of financial and other resources, and a commitment to authentic and open dialogue. While modest and short-term, supplemental funding can strengthen organizational relationships and promote effective collaboration on community-facing activities; it can also lead to improved research engagement and translation of evidence to practice.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}